Ancrod in the treatment of acute ischemic stroke. A review of clinical data

Cerebrovascular Diseases

Volumn 8, Issue SUPPL. 1, 1998, Pages 23-28

  Atkinson, Richard P ^a  

^a Mercy General Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANCROD; FIBRINOGEN;

BLOOD CLOTTING; BLOOD VISCOSITY; BRAIN BLOOD FLOW; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONFERENCE PAPER; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE AGGREGATION; TREATMENT OUTCOME;

EID: 0031973655     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000047500     Document Type: Conference Paper

References (18)

1. Demers C, Ginsberg JS, Brill-Edwards P, et al: Rapid anticoagulation using ancrod for heparin induced thrombocytopenia. Blood 1991;78: 219-249.
2. Dormandy J, Reid H: Controlled defibrination in the treatment of peripheral vascular disease. Angiology 1978;29:80-88.
3. Bell WR, Pitney WR, Goodwin JF: Therapeutic defibrination in the treatment of thrombotic disease. Lancet 1968;i:490-493.
4. Hossmann V, Heiss W-D, Bewermeyer H, Wiedemann G: Controlled trial of ancrod in ischemic stroke. Arch Neurol 1983;40:803-808.
5. The Ancrod Stroke Study Investigators: Ancrod for the treatment of acute ischemic brain infarction. Stroke 1994;25:1755-1759.
6. Ehringer H, Dudczak R, Lechner K: A new approach in the treatment of peripheral arterial occlusions: Defibrination with arvin. Angiology 1974;25:279-289.
7. Ehrly AM: Improvement of the flow properties of blood: A new therapeutical approach in occlusive arterial disease. Angiology 1976;27: 188-196.
8. Soutar RL, Ginsberg JS: Anticoagulant therapy with ancrod. Crit Rev Oncol Hematol 1993;15: 23-33.
9. Thomas DJ, Du Boulay GH, Marshall J, et al: Effect of haematocrit on cerebral blood-flow in man. Lancet 1977;ii:941-943.
10. Thomas DJ, Du Boulay GH, Marshall J, et al: Prevention of stroke: The viscosity factor; in Meyer JS, Lechner H, Reivich M, et al (eds): Cerebral Vascular Disease 2. Amsterdam, Excerpta Medica, 1979, pp 211-215.
11. The Hemodilution in Acute Stroke Study Group: Hypervolemic hemodilution treatment of acute stroke. Stroke 1989;20:317-323.
12. Ringelstein EB, Mauckner A, Schneider R, Sturm W, Doering W, Wolf S, Maurin N, Willmes K, Schlenker M, Bruckmann H, Eschenfelder V: Effects of enzymatic blood defibrination in subcortical arteriosclerotic encephalopathy. J Neurol Neurosurg Psychiatry 1988;51:1051-1057.
13. Schneider R, Ringelstein EB, Zeumer H, Kiesewetter H, Jung F: The role of plasma hyperviscosity in subcortical arteriosclerotic encephalopathy (Binswanger's disease). J Neurol 1987;234:67-73.
14. Olinger CP, Brott TG, Barsan WG, Hedges J, Glas-Greenwalt P, Pollak V, Spilker J, Eberle R: Use of ancrod in acute or progressing ischemic cerebral infarction. Ann Emerg Med 1988;17:1208-1209.
15. Pollak VE, Glas-Greenwalt P, Olinger CP, Wadhwa N, Myre S: Ancrod causes rapid thrombolysis in patients with acute stroke. Am J Med Sci 1990;299:319-325.
16. Kim S, Wadwha N, Kant KS, Pollak V, Glas-Greenwalt P, Weiis M, Hong C: Fibrinolysis in glomerulonephritis treated with ancrod: Renal functional, immunologic, and histopathologic effects. Q J Med 1988;69:875-895.
17. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Tissue plaminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.
18. Levy DE: 21st International Joint Conference of Stroke and Cerebral Circulation; San Antonio, January 1996 (no published abstract).